The updated mRNA-1273.815 COVID-19 vaccine was significantly protective against hospitalization and medically attended outcomes among adults in the United States.

HHS is re-evaluating a nearly $600 million contract with Moderna to develop and test vaccines against flu viruses that could ...

Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...

We recently compiled a list of the 10 Stocks Lead Wednesday’s Charge, Mirror Broader Gains. In this article, we are going to ...

Effectiveness of 2024-25 COVID-19 vaccination against a COVID-19–associated ED/UC visit was 33% (95% confidence interval [CI] ...

The current COVID-19 vaccine is 33% effective at preventing emergency department or urgent care visits among adults of all ages. It also is 45% to 46% effective at preventing hospitalizations in older ...

In an early clinical trial, an experimental norovirus vaccine given as a pill produced defensive responses exactly where it counts—in the saliva of older people most vulnerable to the explosive ...

The CDC has sequenced bird flu viruses from people in Nevada and Wyoming, and the Trump Administration has released a ...

A team of Yale researchers recently published promising results from a clinical trial testing the effectiveness of a new ...

the vaccine efficacy and safety of mRNA-1345; the potential for mRESVIA to reduce disease burden from RSV; Moderna's expectation that the MITC will be fully operational later this year; and Moderna's ...

the vaccine efficacy and safety of mRNA-1345; the potential for mRESVIA to reduce disease burden from RSV; Moderna's expectation that the MITC will be fully operational later this year ...